| Summary: | 碩士 === 長庚大學 === 生化與生醫工程研究所 === 100 === In recent years, colorectal cancer has ranked in the most common cancer and the third most frequent cause deaths in Taiwan. Although there are some molecular target drugs available for cancers, there appears to be urgent needs for the colorectal cancer due to its unusual growth signals and complicated pathogenic mechanisms. Our previous study by using LC - MS / MS to analyze intestinal tissues from colorectal cancer patients, we have discovered several targets with high expression in colorectal carcinoma, and PLSCR1 may play an important role in colorectal cancer carcinogenesis. Here we intend to evaluate if PLSCR1 with potential of inhibiting cell growth for colorectal cancer. First, the PLSCR1 expression in colorectal cancer cells was analyzed by western blotting. We found that PLSCR1 in HT29 is the highest expressed among the other cell lines. Then the effect of treating PLSCR1 antibody was determined on the cell growth of HT29. It showed more suppressive effects on cell growth as the antibody dose increased. Among them, 5μg/ml was effective and the significant inhibition peaked on the third day. Also, similar inhibition effects on cell growth WiDr , HCT15 and LOVO of were found when treating with the antibody. These results provide the evidence for developing PLSCR1 as a potential targeting therapy for colon cancer.
|
|---|
